Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2014. The report serves as a notification of transactions involving Directors and Persons Discharging Managerial Responsibility (PDMRs) or connected persons, specifically regarding the GSK 401K plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific internal plan transactions rather than a financial performance report.
Material Changes
No material changes to the company's financial position or operations are reported. The filing details a revaluation of the cash element of a notional investment held within the GSK 401K plan, which is notionally held in GSK American Depositary Shares (ADSs).
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly reports a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(c).
Key Facts for Investor Verification
- Transaction Date: July 18, 2014.
- Notification Date: July 21, 2014.
- Transaction Type: Increase in notional allocation of ADSs within the GSK 401K plan following a revaluation.
- Price per ADS: $53.72.
- Individuals Involved: Dr. M. Slaoui (Director/PDMR) had no change in allocation; Dr. K. Slaoui (Connected Person) received an increase of 4 ADSs.